US › Healthcare

ImmunoPrecise Antibodies Ltd. (HYFT)

US · Healthcare · Biotechnology

$1.36+0.74%

Last close · 2026-08-04

Latest quarter · ended 2026-04-30

Revenue

$4.1M

Revenue YoY

-41.6%

Net profit

$-3.8M

Profit YoY

-77.3%

EPS

$-0.06

EPS estimate

$-0.05

Net margin

-93.9%

EPS came in at -0.06 against a street estimate of -0.05 — a miss of 20.0%.

Key statistics

Market cap

$60.6M

Forward P/E

0.0

P/B

7.24

Book value

$0.18

EPS (TTM)

$-0.24

52-week high

$3.25

52-week low

$0.99

50-day MA

$1.55

200-day MA

$1.56

Beta

0.83

Analyst view

with an average price target of $4.33.

Shareholding

Insiders

9.14%

Institutions

9.94%

Largest institutional holders

Fund	Stake
Ingalls & Snyder LLC	6.22%
Susquehanna International Group, LLP	1.14%
Renaissance Technologies Corp	0.50%
XTX Topco Ltd	0.37%
Citadel Advisors Llc	0.32%
Jane Street Group LLC	0.27%
Bank of Montreal	0.15%
BMO Capital Markets Corp.	0.15%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ImmunoPrecise Antibodies Ltd. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.